Merck Sharp & Dohme is recalling 106,503 vials of Zerbaxa (ceftolozane and tazobactam) 1.5g per vial for injection. This voluntary recall was initiated because several batches of the medication failed sterility tests, with some testing positive for the bacterium Ralstonia pickettii. While the specific vials sold to the public met safety standards at the time of release, they were manufactured on the same equipment as the contaminated batches, creating a risk of infection.
If a patient receives a non-sterile injection contaminated with Ralstonia pickettii, it can lead to serious, life-threatening infections, especially in those with weakened immune systems or underlying health conditions. No injuries or specific patient infections have been reported to date for the distributed lots.
Pharmacy refund
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.